---
title: "Entyvio (vedolizumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Entyvio (vedolizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Entyvio work (mechanism of action)? What is the half-life of Entyvio? What are the inactive ingredients in Entyvio? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/entyvio/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab), all indications: Pharmacology questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)  
Indication pages: [Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)

## Mechanism

<a id="entyvio-mechanism"></a>

### How does Entyvio work (mechanism of action)?

> “Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin 
> and blocks the interaction of α4β7 integrin with mucosal addressin cell adhesion molecule-1 
> (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium 
> into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit 
> function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 
> integrins with vascular cell adhesion molecule-1 (VCAM-1).
> The α4β7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes 
> that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed 
> on gut endothelial cells and plays a critical role in the homing of T-lymphocytes to gut 
> lymph tissue. The interaction of the α4β7 integrin with MAdCAM-1 has been implicated as 
> an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis 
> and Crohn’s disease.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

## Pharmacokinetics

<a id="entyvio-half-life"></a>

### What is the half-life of Entyvio?

> “Vedolizumab clearance depends on both linear and nonlinear pathways; the nonlinear 
> clearance decreases with increasing concentrations. Population pharmacokinetic analyses 
> indicated that the linear clearance was approximately 0.16 L/day, the serum half-life was 
> approximately 26 days, and the distribution volume was approximately 5 L.”

Source: [ENTYVIO: Prescribing information, page 5, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=5)

## Components

<a id="entyvio-inactive-ingredients"></a>

### What are the inactive ingredients in Entyvio?

> “Each single-dose vial contains 300 mg vedolizumab, arginine hydrochloride (131.7 mg), 
> histidine (23 mg), histidine monohydrochloride (21.4 mg), polysorbate 80 (3 mg), and 
> sucrose (500 mg).”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

> “Each single-dose prefilled syringe or single-dose prefilled pen (ENTYVIO PEN) contains 108 mg
> vedolizumab, arginine hydrochloride (17.77 mg), citric acid monohydrate (0.18 mg), histidine 
> (3.86 mg), histidine monohydrochloride (1.86 mg), polysorbate 80 (1.35 mg), sodium citrate 
> dihydrate (4.71 mg) and Sterile Water for Injection, USP, at a pH of 6.5.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

## Related pages
- [Medical information: Entyvio (vedolizumab): All indications](https://www.evicenter.com/medical-information/entyvio)
- [Indication](https://www.evicenter.com/medical-information/entyvio/indication)
- [Safety](https://www.evicenter.com/medical-information/entyvio/safety)
- [Specific populations](https://www.evicenter.com/medical-information/entyvio/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/entyvio/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio/access-and-coverage)
